(Q37892595)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

Melanoma vaccines: developments over the past 10 years (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author

Christopher W. Schmidt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Jonathan Cebon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Oliver Klein

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Ashley Knights

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Ian D Davis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Weisan Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

853-873

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

Melanoma immunology: past, present and future.

5 February 2020

cites work

1 reference

Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy

21 January 2018

1 reference

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

Recent advances and hurdles in melanoma immunotherapy.

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression

21 January 2018

1 reference

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

21 January 2018

1 reference

Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma

21 January 2018

1 reference

Cytokines and their relationship to the symptoms and outcome of cancer.

21 January 2018

1 reference

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.

21 January 2018

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

21 January 2018

1 reference

Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines

21 January 2018

1 reference

Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.

21 January 2018

1 reference

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

21 January 2018

1 reference

Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood

21 January 2018

1 reference

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

21 January 2018

1 reference

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

21 January 2018

1 reference

Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.

21 January 2018

1 reference

Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.

21 January 2018

1 reference

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

21 January 2018

1 reference

Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses

21 January 2018

1 reference

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.

21 January 2018

1 reference

A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.

21 January 2018

1 reference

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells

21 January 2018

1 reference

Combining MHC tetramer and intracellular cytokine staining for CD8(+) T cells to reveal antigenic epitopes naturally presented on tumor cells.

21 January 2018

1 reference

Designing CD8+ T cell vaccines: it's not rocket science (yet).

21 January 2018

1 reference

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

21 January 2018

1 reference

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

Post-translational modifications of naturally processed MHC-binding epitopes

21 January 2018

1 reference

Post-translationally modified T cell epitopes: immune recognition and immunotherapy

21 January 2018

1 reference

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

21 January 2018

1 reference

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells

21 January 2018

1 reference

The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement

21 January 2018

1 reference

Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A.

21 January 2018

1 reference

DNA vaccines: ready for prime time?

21 January 2018

1 reference

Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity

21 January 2018

1 reference

Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination

21 January 2018

1 reference

MHC class I antigen presentation: learning from viral evasion strategies

21 January 2018

1 reference

21 January 2018

1 reference

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy

21 January 2018

1 reference

The use of melanosomal proteins in the immunotherapy of melanoma

21 January 2018

1 reference

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

21 January 2018

1 reference

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

21 January 2018

1 reference

In vivo switching of human melanoma cells between proliferative and invasive states

21 January 2018

1 reference

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

21 January 2018

1 reference

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

21 January 2018

1 reference

The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

21 January 2018

1 reference

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

21 January 2018

1 reference

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients

21 January 2018

1 reference

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

21 January 2018

1 reference

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside

21 January 2018

1 reference

A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside

21 January 2018

1 reference

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

21 January 2018

1 reference

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

21 January 2018

1 reference

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses

21 January 2018

1 reference

Epitope landscape in breast and colorectal cancer.

21 January 2018

1 reference

Complete but curtailed T-cell response to very low-affinity antigen

21 January 2018

1 reference

Epitope density influences CD8+ memory T cell differentiation

21 January 2018

1 reference

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity

21 January 2018

1 reference

Immune response against dying tumor cells

21 January 2018

1 reference

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

Heat shock protein 70-associated peptides elicit specific cancer immunity

21 January 2018

1 reference

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

21 January 2018

1 reference

The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation

21 January 2018

1 reference

Efficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independent

21 January 2018

1 reference

Antigens for cancer immunotherapy.

21 January 2018

1 reference

Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological Pharmacodynamics

21 January 2018

1 reference

Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group

21 January 2018

1 reference

Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma

21 January 2018

1 reference

Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery

21 January 2018

1 reference

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

21 January 2018

1 reference

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

Therapeutic vaccines for melanoma: current status

21 January 2018

1 reference

Immunotherapy: Vaccine trials in melanoma -- time for reflection

21 January 2018

1 reference

Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine

21 January 2018

1 reference

Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa

21 January 2018

1 reference

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

A new approach in specific, active immunotherapy

21 January 2018

1 reference

Clinical trials with VMO for melanoma

21 January 2018

1 reference

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma

21 January 2018

1 reference

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

21 January 2018

1 reference

A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer

21 January 2018

1 reference

Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine

21 January 2018

1 reference

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

21 January 2018

1 reference

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma

21 January 2018

1 reference

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

21 January 2018

1 reference

Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma

21 January 2018

1 reference

In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients

21 January 2018

1 reference

Antigen-pulsed CD8alpha+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node.

21 January 2018

1 reference

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results

21 January 2018

1 reference

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

Role of imiquimod in skin cancer treatment

21 January 2018

1 reference

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant

21 January 2018

1 reference

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

21 January 2018

1 reference

Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery

21 January 2018

1 reference

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

21 January 2018

1 reference

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma

21 January 2018

1 reference

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma

21 January 2018

1 reference

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

21 January 2018

1 reference

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

21 January 2018

1 reference

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial

21 January 2018

1 reference

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

21 January 2018

1 reference

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

21 January 2018

1 reference

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

21 January 2018

1 reference

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets

21 January 2018

1 reference

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

Found in translation: the human equivalent of mouse CD8+ dendritic cells

21 January 2018

1 reference

Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.

21 January 2018

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.

21 January 2018

1 reference

Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood

21 January 2018

1 reference

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

21 January 2018

1 reference

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

21 January 2018

1 reference

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma

21 January 2018

1 reference

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

21 January 2018

1 reference

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report

21 January 2018

1 reference

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

21 January 2018

1 reference

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

Genome-wide analysis of cancer/testis gene expression

21 January 2018

1 reference

A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples

21 January 2018

1 reference

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

21 January 2018

1 reference

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21692705%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference